C
Christopher D. Lao
Researcher at University of Michigan
Publications - 127
Citations - 24365
Christopher D. Lao is an academic researcher from University of Michigan. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 35, co-authored 100 publications receiving 17710 citations.
Papers
More filters
Journal ArticleDOI
Morphomics predicts response to ipilimumab in patients with stage IV melanoma.
TL;DR: This work explored the possibility that morphomics may predict response among stage IV melanoma patients treated with ipilimumab, and found that it could be an objective surrogate for underlying physiology.
Journal ArticleDOI
SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma.
Alain Algazi,Megan Othus,Adil Daud,Janice M. Mehnert,Christopher D. Lao,Ragini R. Kudchadkar,Kenneth F. Grossmann,Roger S. Lo,James C. Moon,John M. Kirkwood,Antoni Ribas +10 more
TL;DR: Combined BRAF and MEK inhibition yields improved response rates and overall survival compared with BRAF inhibitor monotherapy in BRAF mutant melanoma patients, according to Robert et al., 201...
Journal ArticleDOI
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
F. Stephen Hodi,Paul B. Chapman,Mario Sznol,Christopher D. Lao,Rene Gonzalez,Michael Smylie,Gregory A. Daniels,John A. Thompson,Ragini R. Kudchadkar,William H. Sharfman,Michael B. Atkins,David R. Spigel,Anna C. Pavlick,Jose Gerard Monzon,Kevin B. Kim,Scott Ernst,Nikhil I. Khushalani,Wim van Dijck,Maurice Lobo,David Hogg +19 more
TL;DR: In this EAP, nivolumab plus ipilimumab demonstrated high survival rates and safety outcomes consistent with those from randomized clinical trials, further supporting the use of this combination for advanced melanoma across multiple subgroups.
Journal ArticleDOI
Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Jessica Waninger,Vincent T. Ma,Sara Journey,Jeremy Skvarce,Zoey Chopra,Alangoya Tezel,Alex K. Bryant,Charles S. Mayo,Yilun Sun,Kamya Sankar,Nithya Ramnath,Nithya Ramnath,Christopher D. Lao,Jeremy B. Sussman,Jeremy B. Sussman,Leslie A. Fecher,Ajjai Alva,Ajjai Alva,Michael D. Green,Michael D. Green +19 more
TL;DR: In this article, the authors evaluated the outcomes of patients with metastatic cutaneous melanoma based on the M stage category from the AJCC eighth edition and to determine whether these designations continue to inform the prognosis of patients who have received ICIs.
Journal ArticleDOI
Implications of age and conditional survival estimates for patients with melanoma.
Mousumi Banerjee,Christopher D. Lao,Lauren M. Wancata,Daniel G. Muenz,Megan R. Haymart,Sandra L. Wong +5 more
TL;DR: Understanding the conditional 5-year disease-specific survival of melanoma based on age and stage can help patients and physicians, informing decision-making about treatment and surveillance.